Some Targeted and Immune Checkpoint Therapies for Non–Small Cell Lung Cancer
Target | Drug |
|---|---|
ALK rearrangement | Alectinib Brigatinib Ensartinib Lorlatinib |
BRAF mutation | Dabrafenib + trametinib Encorafenib + binimetinib |
EGFR mutation | Amivantamab + lazertinib Osimertinib |
EGFR exon 20 | Amivantamab |
Inhibit blood vessel growth | Bevacizumab Ramucirumab |
Immune activation (checkpoint inhibitors) | Atezolizumab Cemiplimab Durvalumab Ipilimumab Nivolumab Pembrolizumab |
ROS rearrangement | Crizotinib Entrectinib Repotrectinib Taletrectinib |
MET exon 14 skipping mutation | Capmatinib Tepotinib |
RET rearrangement | Pralsetinib Selpercatinib |
NTRK1, NRTK2, or NRTK3 gene fusion | Entrectinib Larotrectinib Repotrectinib |
NSCLC = Non–small cell lung cancer. | |
In these topics